Pre-Test Understanding TYK2 as a Therapeutic Target in the Management of Moderate to Severe Psoriasis Pre-Test Which of the following statements regarding the inhibition of TYK2 inhibitors regulate signal transduction of receptors located downstream of IL-23 and IL-12 pathways targeting extracellular JAKs TYK2 inhibitors regulate signal transduction of receptors located downstream of IL-23 and IL-12 pathways and target intracellular JAKs TYK2 inhibitors regulate signal transduction of receptors located upstream of IL-23 and IL-12 pathways targeting extracellular JAKs TYK2 inhibitors regulate signal transduction of receptors located upstream of IL-23 and IL-12 pathways targeting intracellular JAKs Unsure Long-term maintenance data demonstrate durable clinical efficacy and a well-tolerated safety profile with 82.4% of patients achieving Psoriasis Area and Severity Index (PASI) 75 response at 2 years with which of the following? Brepocitinib Deucravacitinib Ropsacitinib Tivozanib Unsure How confident are you in your ability to optimally integrate TYK2 inhibitors into the management of plaque psoriasis? Very Confident Confident Somewhat confident Not very confident Not at all confident
